Abstract
Get full access to this article
View all access options for this article.
References
1.
Loftus
P.
FDA says no to drug evaluated in China. Wall Street J. March 25, 2022; p. A3.
2.Anonymous . Certain ophthalmic products: policy regarding compliance with 21 CFR part 4; guidance for industry . Fed. Regist . 87 :16391 –16393 , 2022 .
3.
Walker
J.
Medicare draws pushback on drug. Wall Street J. February 23, 2022; p. A3.